# Pizarra — PT-pseudo_d3e975d025e6 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3e975d025e6
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 15.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.318 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 15.4 ng/mL
  - Prostate volume: 49.63 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84823215 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.

Vitals: weight 69 kg, height 179 cm, BMI 21.5, BP 127/86 mmHg, HR 72 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results.

History: First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly.

Patient info: tram driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.81 +/- 0.08   (95% CI 0.65-0.98)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.08  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.69 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI report confirm a PI-RADS score of 5 and describe the lesion characteristics?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline values?
  - previous_notes (get_previous_notes) -> What is the prior management context, including prior grade and surveillance pathway?

This case hinges on the detailed findings from the MRI, the PSA trajectory, and the prior management plan to confirm the guideline-based biopsy recommendation.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (15.8 ng/mL), PI-RADS (5), PSA density (0.318 ng/mL²), PSA velocity (0.96 ng/mL/yr), and prior biopsy status (None). It cannot weigh the qualitative information from the mpMRI prose, the specific PSA trajectory details beyond the headline velocity, or the context provided in the previous notes regarding prior management.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests a high probability of biopsy (0.81), but the guideline track record is based on a cohort where the decision hinges on the PI-RADS score and biopsy-naïveté. A PI-RADS 5 is high risk, but the prior does not account for the potential for overdiagnosis, especially given the high csPCa probability (0.84823215). The high aleatoric uncertainty (H=0.69) suggests the data itself is highly mixed, meaning the model might be failing to distinguish between cases where a PI-RADS 5 warrants biopsy versus those where it does not, especially when combined with other factors like PSA velocity.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI report confirm a PI-RADS score of 5 and describe the lesion characteristics?
psa_trend - What is the serial PSA trend and velocity beyond the headline values?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
laboratory panel - What are the full laboratory results?

GUIDELINE ANCHOR
Guidelines suggest biopsy when the mpMRI shows a PI-RADS 3 or higher lesion, and the track record shows a strong match for this criterion in biopsy-naive patients.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_d3e975d025e6", "radiology_report": "Jeroen Bosch Ziekenhuis, 's-Hertogenbosch | 15 January 2025 | mpMRI of the Prostate\n\nClinical indication: Evaluation of persistently elevated PSA (15.8 ng/mL) and clinical suspicion of malignancy.\n\nFINDINGS:\nA glandular capacity of 49.63 mL is recorded. Imaging reveals a discrete, low-signal area within the left peripheral zone, spanning the base through the mid-gland, spanning roughly 18 mm at its widest. High b-value diffusion sequences show intense restriction, mirrored by dark ADC mapping. Post-contrast phases highlight early, localized enhancement compared to adjacent tissue. Capsular integrity remains intact with no seminal vesicle involvement. Pelvic nodes show normal dimensions and structure. No abnormal bone signals appear in the scanned region.\n\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm. Prostate volume 49.63 mL. PSA density 0.318 ng/mL/mL. csPCa probability 0.84823215."}
get_psa_trend
{"case_id": "PT-pseudo_d3e975d025e6", "psa_trend": [{"date": "Jan 2023", "val": 3.9}, {"date": "Jul 2023", "val": 5.5}, {"date": "Jan 2024", "val": 7.8}, {"date": "Jul 2024", "val": 11.1}, {"date": "Jan 2025", "val": 15.8}]}
get_previous_notes
{"case_id": "PT-pseudo_d3e975d025e6", "previous_notes": [{"date": "24 Jan 2024", "author": "Dr. C. Peters (GP)", "text": "Clinical review on 24 January 2024 documented a PSA level of 15.1 ng/mL, following values of 11.6 ng/mL in early 2023 and a peak reading of 22.1 ng/mL during mid-2023. Persistent elevation alongside a fluctuating trajectory led to urological referral for comprehensive assessment and potential multiparametric MRI scheduling. Repeat laboratory work confirmed stable renal parameters. The outpatient visit was coordinated for his preferred morning window."}]}
NOT RETRIEVED
laboratory panel
Left closed because the moderator's agenda did not explicitly ask for the full laboratory panel, and no information from the retrieved documents raised a specific question requiring it.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm.
- PSA trend: Rising velocity of 0.96 ng/mL/yr, with a recent jump to 15.8 ng/mL.
AGAINST sampling this patient now:
- Previous notes: No prior biopsy grade or explicit mention of an active surveillance protocol requiring a protocol biopsy.
WHERE THIS LEANS
The evidence strongly supports the guideline criterion for biopsy due to the PI-RADS 5 finding and the rising PSA velocity, confirming the statistical prior.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI report, PSA trend, previous notes) strongly support the guideline criterion for biopsy (PI-RADS 5 and rising PSA velocity). The record is sufficient to proceed to the final decision stage, although the laboratory panel remains unretrieved.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The guideline criterion mandates biopsy for a PI-RADS 5 lesion, which was confirmed by the retrieved MRI report. This finding was combined with the rising PSA velocity of 0.96 ng/mL/yr and the elevated PSA level of 15.8 ng/mL, which were decisive factors. The statistical prior also suggested biopsy, and the evidence confirmed the protocol recommendation.

Variables that carried weight: age=important, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
